Figure 4.

A representative ex-vivo radionuclide image at the papillary muscle short-axis level after injection with 123I-MIBG, which illustrates that there is less uptake in the TMR-treated (LCx) region than in the untreated control (LAD) region.

A representative ex-vivo radionuclide image at the papillary muscle short-axis level after injection with 123I-MIBG, which illustrates that there is less uptake in the TMR-treated (LCx) region than in the untreated control (LAD) region.